# Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/economics-and-cost-effectiveness-of-multiple-sclerosis-therapies-in-the-usa/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Daniel M. Hartung |
| Citations | 95 |
| DOI | 10.1007/s13311-017-0566-3 |
| Fields | Economics, Econometrics and Finance,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://link.springer.com/content/pdf/10.1007/s13311-017-0566-3.pdf |
| OpenAlex ID | https://openalex.org/W2748489847 |
| PMID | 28812229 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Daniel M. Hartung](https://scholariq.org/researchers/daniel-m-hartung/)

## Paper journal

- [Neurotherapeutics](https://scholariq.org/journals/neurotherapeutics/)

## Paper primary topic

- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)

## Paper topics

- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Acute Lymphoblastic Leukemia research](https://scholariq.org/topics/acute-lymphoblastic-leukemia-research/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.